Moderate

Connective tissue disease-associated interstitial lung disease (CTD-ILD; incl. RA, scleroderma, myositis)

ctd-ild · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Interstitial lung disease arising with systemic autoimmune disease - systemic sclerosis, rheumatoid arthritis, idiopathic inflammatory myositis (incl. anti-synthetase, anti-MDA5), Sjogren, mixed connective tissue disease, SLE. Distinct from IPF: many are inflammation-predominant and respond to immunosuppression, while progressive fibrotic phenotypes may need antifibrotics. Needs combined respiratory-rheumatology care.

Red flags

  • Rapidly progressive ILD, esp. anti-MDA5 dermatomyositis (can be fulminant - urgent aggressive immunosuppression)
  • Acute exacerbation of fibrotic ILD
  • New/worsening hypoxaemia
  • Pulmonary hypertension (scleroderma)
  • Opportunistic infection during immunosuppression (e.g. PJP)
  • Scleroderma renal crisis precipitated by high-dose steroids

Assessment

Differential diagnosis

  • Idiopathic pulmonary fibrosis / idiopathic interstitial pneumonias
  • Hypersensitivity pneumonitis
  • Drug-induced ILD (e.g. methotrexate, biologics)
  • Infection (incl. opportunistic in immunosuppressed, e.g. PJP)
  • Pulmonary involvement of vasculitis
  • Heart failure
  • ILD as first presentation of occult CTD (interstitial pneumonia with autoimmune features)

Investigations

  • HRCT thorax - pattern recognition (NSIP common in scleroderma/myositis; UIP more in RA); extent guides prognosis
  • Pulmonary function tests + DLCO (restrictive, reduced gas transfer) - serial testing tracks progression
  • Full autoimmune serology: ANA, ENA panel, anti-Scl-70/RNA-pol III/centromere, RF/anti-CCP, myositis panel (Jo-1, anti-MDA5, others), anti-Ro/La
  • Exclude infection (esp. before/while immunosuppressing) incl. PJP risk assessment
  • Echocardiography (screen pulmonary hypertension, esp. scleroderma)
  • 6-minute walk + oxygen saturation; baseline bloods for immunosuppression monitoring
  • MDT review (respiratory + rheumatology + radiology); lung biopsy rarely needed if CTD and pattern concordant

Management

  • Confirm ILD on HRCT/PFTs and establish the underlying CTD (serology + systemic features); involve rheumatology
  • Characterise phenotype: inflammatory-predominant vs progressive fibrotic, and assess severity/trajectory with serial PFTs
  • Exclude infection and drug-induced ILD before escalating immunosuppression
  • Immunosuppression is first-line for most inflammatory CTD-ILD: corticosteroids plus a steroid-sparing agent (mycophenolate often first choice; cyclophosphamide or rituximab for severe/rapidly progressive, e.g. scleroderma or anti-MDA5 disease)
  • Add an antifibrotic (nintedanib) for progressive pulmonary fibrosis phenotype despite treatment (approved for SSc-ILD and progressive fibrosing ILD)
  • Caution with high-dose steroids in systemic sclerosis (scleroderma renal crisis risk)
  • Supportive care: oxygen if hypoxaemic, pulmonary rehabilitation, vaccination, PJP prophylaxis when heavily immunosuppressed, screen/treat pulmonary hypertension and reflux
  • Monitor response and toxicity with serial PFTs/HRCT; refer refractory/advanced disease for transplant assessment

Drugs & doses

Prednisolone (moderate dose) for inflammatory CTD-ILD; avoid high doses in systemic sclerosis (renal crisis risk) [verify dose]
Mycophenolate mofetil titrated to ~1-1.5 g PO BD - common first-line steroid-sparing agent [verify dose]
Cyclophosphamide (IV pulses) or rituximab for severe/rapidly progressive disease (e.g. scleroderma, anti-MDA5 myositis) [verify protocol]
Nintedanib 150 mg PO BD - antifibrotic for SSc-ILD and progressive fibrosing ILD (GI/hepatic monitoring) [verify eligibility]
Co-trimoxazole 480-960 mg daily/alternate days as PJP prophylaxis during significant immunosuppression [verify dose]
Supplemental oxygen if chronic hypoxaemia; PPI for reflux (esp. scleroderma)

Disposition

Specialist respiratory-rheumatology MDT, usually outpatient. Admit rapidly progressive ILD, acute exacerbation, or respiratory failure (urgent immunosuppression). Transplant referral for advanced/refractory disease.

Complications & pitfalls

  • Progressive fibrosis and respiratory failure
  • Acute exacerbation of ILD (high mortality)
  • Pulmonary hypertension / cor pulmonale
  • Immunosuppression-related infection and drug toxicity
  • Lung cancer risk in fibrotic lung
  • Reduced quality of life, need for transplantation

Exam pearls

  • Unlike IPF, many CTD-ILDs are inflammation-predominant and respond to immunosuppression - distinguishing phenotype is key (ATS/ERS; scleroderma-ILD evidence from SLS-II/SENSCIS).
  • Mycophenolate is a common first-line agent; rituximab/cyclophosphamide for severe or rapidly progressive disease.
  • Nintedanib slows decline in systemic-sclerosis-associated and other progressive fibrosing ILDs (SENSCIS/INBUILD) - used alongside immunosuppression for the fibrotic phenotype.
  • Avoid high-dose corticosteroids in systemic sclerosis - they can precipitate scleroderma renal crisis.
  • Anti-MDA5 dermatomyositis can cause fulminant, rapidly progressive ILD needing urgent aggressive therapy.
  • Always exclude infection and drug-induced ILD before intensifying immunosuppression; manage via a respiratory-rheumatology MDT.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.